• Markets
    • icon
  • Companies
ATH · ASX

Alterity Therapeutics Ltd. (ASX:ATH)

AU$0.003

 -0.001 (-25.0%)
ASX:Live
28/11/2023 04:10:31 PM
Volume Spike (Realtime) Near Support (Realtime) Near Support Near 52 Week Low HALO Ords +4
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ATH Overview

ATH Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About ATH

Website

Alterity Therapeutics Ltd.

Telephone

61.3.9349.4906

Address

Suite 4 Level 14 350 Collins Street Melbourne, Victoria (VIC) 3000

Description

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

ATH Price Chart

Key Stats

Market Cap

AU$9.76M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.01

Trade Value (12mth)

AU$2,989.00

1 week

0%

1 month

-42.86%

YTD

-60%

1 year

-60%

All time high

1.5

Key Fundamentals

EPS 3 yr Growth

-62.000%

EBITDA Margin

N/A

Operating Cashflow

-$20m

Free Cash Flow Return

-68.60%

ROIC

-47.20%

Interest Coverage

N/A

Quick Ratio

6.20

Other Data

Shares on Issue (Fully Dilluted)

2440m

HALO Sector

Healthcare

Next Company Report Date

30-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ATH Announcements

Latest Announcements

Date Announcements

31 October 23

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

31 July 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 23

Appendix 4C and Quarterly Cash Flow Report

×

Appendix 4C and Quarterly Cash Flow Report

31 August 23

Alterity Presents New Data on Multiple System Atrophy

×

Alterity Presents New Data on Multiple System Atrophy

31 August 23

Appendix 4E and Annual Report 2023

×

Appendix 4E and Annual Report 2023

31 August 23

Appendix 4G and Corporate Governance Statement 2023

×

Appendix 4G and Corporate Governance Statement 2023

31 August 22

Appendix 4E & Annual Report 2022

×

Appendix 4E & Annual Report 2022

31 August 22

Appendix 4G and Corporate Governance Statement 2022

×

Appendix 4G and Corporate Governance Statement 2022

30 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

30 May 23

ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder

×

ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder

30 June 22

Alterity receives a $4.1 million R&D Tax Refund

×

Alterity receives a $4.1 million R&D Tax Refund

30 January 23

ATH434 Prevents Brain Cell loss in Parkinsons Animal Model

×

ATH434 Prevents Brain Cell loss in Parkinsons Animal Model

30 August 19

Appendix 4E & Annual Report 2019

×

Appendix 4E & Annual Report 2019

29 December 22

New US patent for compounds to treat neurodegeneration

×

New US patent for compounds to treat neurodegeneration

29 April 22

Appendix 4C and Quarterly Cash Flow Report

×

Appendix 4C and Quarterly Cash Flow Report

28 September 22

Change in substantial holding

×

Change in substantial holding

28 October 22

Appendix 4C and Quarterly Cash Flow Report

×

Appendix 4C and Quarterly Cash Flow Report

28 January 22

New publication shows ATH434 rescues neurons in MSA model

×

New publication shows ATH434 rescues neurons in MSA model

28 February 23

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

28 February 22

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

27 November 23

ATH presents Novel Biomarker Data for Evaluation of MSA

×

ATH presents Novel Biomarker Data for Evaluation of MSA

27 June 22

Notification of cessation of securities - ATH

×

Notification of cessation of securities - ATH

27 January 22

Appendix 4C and Quarterly Cash Flow Report

×

Appendix 4C and Quarterly Cash Flow Report

27 April 23

Appendix 4C and Quarterly Cash Flow Report

×

Appendix 4C and Quarterly Cash Flow Report

27 April 22

UK Regulatory Authorisation to Proceed with Phase 2 Trial

×

UK Regulatory Authorisation to Proceed with Phase 2 Trial

26 September 22

Wearable Sensor Data from bioMUSE Natural History Study

×

Wearable Sensor Data from bioMUSE Natural History Study

26 October 22

Presentation of bioMUSE MRI data

×

Presentation of bioMUSE MRI data

ATH Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 40.0 41.1 -7.5 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 52.8 5.5 4.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -36.5 -39.7 -117.9 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.01 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.01 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 112.1 0.8 -36.6 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 1,697 2,406 2,428 Lock Lock Lock
Basic m Lock Lock Lock Lock 1,697 2,406 2,428 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 19 21 18 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 33.0 28.1 -88.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -19 -21 -18 Lock Lock Lock
     Growth % Lock Lock Lock Lock -41.1 -5.8 10.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -20 -21 -19 Lock Lock Lock
     Growth % Lock Lock Lock Lock -40.5 -5.7 10.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -19 -17 -18 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -4 -5 -4 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -15 -13 -14 Lock Lock Lock
     Growth % Lock Lock Lock Lock -13.8 16.1 -7.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -17 -12 -20 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 37 16 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -17 -12 -20 Lock Lock Lock
     Growth % Lock Lock Lock Lock -83.5 28.3 -61.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 28 35 16 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 34 41 27 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -28 -35 -16 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 3 6 5 Lock Lock Lock
Equity $m Lock Lock Lock Lock 30 35 23 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 31 36 23 Lock Lock Lock
     Growth % Lock Lock Lock Lock 326.6 16.5 -35.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -45.6 -31.1 -50.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -50.2 -36.2 -60.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -103.5 -62.4 -63.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -81.3 -38.9 -47.2 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -92.0 -37.4 -68.6 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.4 1.7 0.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -92.1 -97.8 -68.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 10.9 7.1 6.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 10.9 7.1 6.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 84.0 84.6 58.3 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -564.9 -212.0 -457.2 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -45.6 -31.1 -50.5 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.2 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -50.2 -36.2 -60.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -50.2 -36.2 -60.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 5,821.4 13,931.3 7,866.4 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -5,821.4 -13,931.3 -7,866.4 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ATH Shortsell

Frequently Asked Questions

The current share price of Alterity Therapeutics Ltd. (ATH:ASX) is AU$0.003.
The 52-week high share price for Alterity Therapeutics Ltd. (ATH:ASX) is AU$0.01.
The 52-week low share price for Alterity Therapeutics Ltd. (ATH:ASX)? is AU$0.00.
Alterity Therapeutics Ltd. (ATH:ASX) does not pay a dividend.
Alterity Therapeutics Ltd. (ATH:ASX) does not pay a dividend.
Alterity Therapeutics Ltd. (ATH:ASX) has a franking level of 0%.
Alterity Therapeutics Ltd. (ATH:ASX) is classified in the Healthcare.
The current P/E ratio for Alterity Therapeutics Ltd. (ATH:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.